Navigation Links
SPO Updates Shareholders on 2012 Corporate Strategy
Date:1/24/2012

NEW YORK, January 24, 2012 /PRNewswire/ --

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today an update to its shareholders on the Company's product and revenue generation strategy for fiscal 2012 primarily based on the completion of development and launch of a new range of consumer wellness devices.

SPO currently has three products in development stage which utilize the Company's proprietary intellectual property portfolio. SPO anticipates revenue generation via a recently contracted strategic distribution partner for its consumer wellness bracelet to commence during the second half of 2012.

The products under development are:

(i) A new and unique consumer wellness bracelet designed to measure a person's overall daily activity level, especially useful for the overweight or obese. The wellness bracelet, both for children and adults, contains  innovative features including display functionality and a time-piece which continuously measures the number of daily activities and calories burned against a recommended goal.

(ii) A sports and wellness wristwatch using SPO' vital sign technology for continuous heart rate measurement, which negates the need for the traditional chest-strap currently being used by most sports watch manufacturers. The ability to accurately and reliably measure heart-rate from the wrist area during motion has been a major challenge for the sports watch industry which typically required a chest-strap for acquiring continuous heart-rate readings.

(iii) An innovative home-baby monitoring device for continuous measurement of wellness information to the parent or caregiver, while the baby is sleeping. This parental reassurance tool gives the company a technological competitive edge in providing an innovative, high performance solution for a market application that is applicable to most family homes.

Michael Braunold, Chief Executive Officer of SPO commented: "The general wellness sector is a mass-market opportunity for our technology, enabling monitoring of information in conjunction with leisure related activities. In addition, our baby monitoring product will add a new element to parental reassurance. Our strategy is to partner with consumer product manufacturers and distributors to enable our innovative bracelet, sports watch and baby monitoring products to be manufactured and commercialized at a time when the market is actively seeking solutions to wellness problems facing society as a whole."

About SPO

SPO (SPOM) is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spoglobal.com

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, market acceptance of our products and new product applications, timing of new product launches, success of the Company's rebranding program, product performance, size of prospective markets, revenue assessments, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2010. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact regarding this release:
SPO
investors@spoglobal.com
+1-866-991-7766


'/>"/>
SOURCE SPO Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. Bacterin International Updates Fourth Quarter and Full Year 2010 Financial Results
4. Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance
5. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
6. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50
7. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
8. NEURO-BIOTECH CORPORATION: Updates and latest developments
9. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
10. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
11. China-Biotics Provides Further Updates on Qingpu New Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):